Science and Research

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA2)

The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).

Study details
Study-ID: NCT03733444, 2018-001406-29
Study-ID: NCT03733444, 2018-001406-29
DZL Disease Area: DPLD
DZL Disease Area: DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 05.11.2018
Completion Date: 30.03.2021
Status: Terminated
Status: Terminated
DZL recruiting center
Link to Study


chevron-down